Relmada targets year-end IND filings for NDV-01 and sepranolone, reports $217.7M cashAug 6Quarterly updateRelmada Therapeutics, Inc.sustained-release gemcitabine-docetaxel
Relmada names Bipin Dalmia as Chief Business OfficerJul 28PeopleRelmada Therapeutics, Inc.sustained-release gemcitabine-docetaxel
Sign inSign in